Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509916 | 0.74 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5512967 | 0.74 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5514482 | 0.71 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20239746 | 0.71 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13448111 | 0.71 | SLC1A3 (0.39) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28270588 | 0.70 | MAPK1 (0.42) | — | |
| SCHEMBL4982402 | 0.69 | MMP8 (0.35) | MMP8 | |
| SCHEMBL25131984 | 0.69 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1MMP8 | |
| SCHEMBL12868857 | 0.69 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29104414 | 0.69 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313386-B1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP ASSETS BV (NL) | 2012-01-04 | — | — | EP | disclosed |
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-10-06 | — | — | US | disclosed |
| EP-2313386-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP Assets B.V. (NL) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010010165-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP ASSETS BV (NL) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | KHK, AGTR2, HK2 | SLC1A3 1279/4885SLC1A2 843/4885SLC1A1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.